SAN DIEGO (September 5, 2024) — Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, commends the U.S. Food & Drug Administration’s
SAN DIEGO (July 25, 2024) — Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, is launching a new line of
SAN DIEGO, March 4, 2024 – Amprion is pleased to announce its presence at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and related
SAN DIEGO, February 9, 2024 – Amprion is pleased to be affiliated with a new scientific paper published in Alzheimer’s & Dementia, entitled “Investigating alpha-synuclein co-pathology
HCP Live, December 8, 2023 Alzheimer disease (AD) is defined by the presence of amyloid plaques and tangles in the brain leading to progressive memory
SAN DIEGO, August 15, 2023 – Amprion has been contracted by the National Institutes of Health (NIH) Intramural Research Program’s Center for Alzheimer’s and Related Dementias (CARD)
SAN DIEGO, August 15, 2023 – Amprion, a global leader in neurodegenerative disease diagnostics, continues to fortify its Intellectual Property surrounding the company’s proprietary methodology
SAN DIEGO, March 27, 2023 – Amprion is pleased to announce its attendance at the AD/PD™ 2023 International Conference on Alzheimer’s and Parkinson’s Diseases and
A pioneer in the science of detecting misfolded proteins, Amprion advances the diagnosis of brain disorders. Our SAAmplify™-ɑSYN Test aids physicians in diagnosing Parkinson’s, Lewy body dementia, and Alzheimer’s with Lewy body variant. We plan to launch more biomarker tests in the future.
Our flagship α-synuclein SAA, SYNTap®, is getting a makeover.
Effective September 9, 2024, SYNTap will be
And stay tuned for the SAAmplify family of panels, coming soon!
